Filing Details
- Accession Number:
- 0001114220-18-000100
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-10-30 16:07:47
- Reporting Period:
- 2018-10-29
- Accepted Time:
- 2018-10-30 16:07:47
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1114220 | Keryx Biopharmaceuticals Inc | KERX | Pharmaceutical Preparations (2834) | 134087132 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1640447 | F. John Neylan | C/O Keryx Biopharmaceuticals, Inc. One Marina Park Drive, 12Th Floor Boston MA 02210 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2018-10-29 | 1,253 | $3.07 | 149,435 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Footnotes
- Sale of a total of 1,253 shares of common stock was made in order to satisfy Mr. Neylan's income tax withholding obligation upon the vesting of 4,479 shares of restricted stock on October 28, 2018. Mr. Neylan had no discretion with respect to such sale, which was transacted in accordance with the Issuer's corporate policies regarding the vesting of restricted stock.
- Includes 70,102 shares of restricted stock.
Billionaire Hedge Funds
